Bucindolol attenuates the vascular remodeling of pulmonary arteries by modulating the expression of the endothelin-1 A receptor in rats with pulmonary arterial hypertension

Seolin, Bruna Gazzi de Lima; Hennemann, Matheus Mittmann; Fernandes, Rafael Oliveira; Colombo, Rafael; Bonetto, Jéssica Hellen Poletto; Teixeira, Rayane Brinck; Khaper, Neelam; Godoy, Alessandra Eifler Guerra; Litvin, Isnard Elman; Araújo, Alex Sander da Rosa; Schenkel, Paulo Cavalheiro

doi:10.1016/j.biopha.2018.01.127

Cited by 7 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with PAH disorder have increased ET-1 levels typically found in the lungs and circulation, thus allowing ET-1 to be a promising treatment target. 219 – 221 The NO pathway is targeted through phosphodiesterase-5 (PDE5) inhibitors, including tadalafil, sildenafil, riociguat and soluble guanylate cyclase (sGC) stimulator. 222 Restoring cGMP levels is central to therapy in the NO-sGC-cyclic guanosine monophosphate (cGMP) axis.…”

Section: Pulmonary Arterial Hypertension (Pah)mentioning

confidence: 99%

Multifunctional nanoparticle-mediated combining therapy for human diseases

Li,

Peng,

Zoulikha

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Combining existing drug therapy is essential in developing new therapeutic agents in disease prevention and treatment. In preclinical investigations, combined effect of certain known drugs has been well established in treating extensive human diseases. Attributed to synergistic effects by targeting various disease pathways and advantages, such as reduced administration dose, decreased toxicity, and alleviated drug resistance, combinatorial treatment is now being pursued by delivering therapeutic agents to combat major clinical illnesses, such as cancer, atherosclerosis, pulmonary hypertension, myocarditis, rheumatoid arthritis, inflammatory bowel disease, metabolic disorders and neurodegenerative diseases. Combinatorial therapy involves combining or co-delivering two or more drugs for treating a specific disease. Nanoparticle (NP)-mediated drug delivery systems, i.e., liposomal NPs, polymeric NPs and nanocrystals, are of great interest in combinatorial therapy for a wide range of disorders due to targeted drug delivery, extended drug release, and higher drug stability to avoid rapid clearance at infected areas. This review summarizes various targets of diseases, preclinical or clinically approved drug combinations and the development of multifunctional NPs for combining therapy and emphasizes combinatorial therapeutic strategies based on drug delivery for treating severe clinical diseases. Ultimately, we discuss the challenging of developing NP-codelivery and translation and provide potential approaches to address the limitations. This review offers a comprehensive overview for recent cutting-edge and challenging in developing NP-mediated combination therapy for human diseases.

show abstract

Section: Pulmonary Arterial Hypertension (Pah)mentioning

confidence: 99%